Point72 Asset Management
PRME icon

Point72 Asset Management’s Prime Medicine PRME Stock Holding History

Point72 Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-551,030
Closed -$1.91M – 4335
2025
Q4 		$1.91M Buy
+551,030
New +$2.45M ﹤0.01% 2502
2025
Q1 		– Sell
-68,528
Closed -$200K – 2439
2024
Q4 		$200K Buy
+68,528
New +$241K ﹤0.01% 1882

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Point72 Asset Management's PRME Position: Q1 2026 in Review

Point72 Asset Management sold out of Prime Medicine (PRME) in Q1 2026, closing a stake of 551,030 shares — an estimated $1.91M sold.

Point72 Asset Management first reported a position in PRME in Q4 2024 and held it in 2 quarters. The position peaked at $1.91M in Q4 2025. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Point72 Asset Management reported no remaining Prime Medicine position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 551,030 Prime Medicine shares in Q1 2026, an estimated $1.91M.
  • Point72 Asset Management first reported a position in Prime Medicine in Q4 2024 and held it in 2 quarters.
  • Point72 Asset Management's Prime Medicine position peaked at $1.91M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.